# A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

> **NCT06844357** · PHASE2,PHASE3 · RECRUITING · sponsor: **Zhejiang Raygene Pharmaceuticals Co., Ltd** · enrollment: 300 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** tirapazamine
- **PROCEDURE:** Transarterial Embolization (TAE)
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT06844357
- **Lead sponsor:** Zhejiang Raygene Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2029-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06844357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06844357, "A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06844357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*